Expression of lineage markers (%) or colony production (per 105 cells) by engrafted human cells in fetal sheep: primary recipients (groups I, II, III) were examined 2 and 6 months after transplantation
| . | Group I . | Group II . | Group III . | Group IV 2 mo . | Group V 2 mo . | Group VI 2 mo . | Group VII 2 mo . | Group VIII 2 mo . | Group IX 2 mo . | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 mo . | 6 mo . | 2 mo . | 6 mo . | 2 mo . | 6 mo . | |||||||
| CD3 | 0.72 | 0.51 | 2.1 | 0.80 | 0.30 | 0 | 0.78 | 0.15 | 0 | 0.22 | 0.08 | 0 |
| CD20 | 0.66 | 0.50 | 0.70 | 0 | 0 | 0 | 0.50 | 0.28 | 0 | 0.53 | 0 | 0 |
| CD33 | — | 0.48 | 1.12 | 1.40 | 0.50 | 0 | 1.08 | 0.77 | 0 | 0.60 | 0.23 | 0 |
| CD34 | 0.32 | 0.18 | 0.20 | 0.09 | 0 | 0 | 0.15 | 0.09 | 0 | 0.19 | < 0.05 | 0 |
| CD45 | 4.8 | 4.1 | 6.3 | 4.3 | 5.6 | 0.18 | 5.20 | 4.40 | < 0.05 | 4.7 | 0.80 | 0 |
| Gly A | 14.6 | 8.9 | 7.8 | 9.3 | 9.2 | 8.6 | 5.3 | 0.48 | 4.3 | 2.6 | 0 | |
| CFU-GM | 9.8 | 8.4 | 15.6 | 11.7 | 11.7 | 0 | 9.1 | 5.2 | 0 | 7.0 | 2.5 | 0 |
| CFU-Mix | 4.9 | 5.2 | 6.8 | 5.9 | 6.2 | 0 | 5.6 | 3.1 | 0 | 4.4 | 0 | |
| . | Group I . | Group II . | Group III . | Group IV 2 mo . | Group V 2 mo . | Group VI 2 mo . | Group VII 2 mo . | Group VIII 2 mo . | Group IX 2 mo . | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2 mo . | 6 mo . | 2 mo . | 6 mo . | 2 mo . | 6 mo . | |||||||
| CD3 | 0.72 | 0.51 | 2.1 | 0.80 | 0.30 | 0 | 0.78 | 0.15 | 0 | 0.22 | 0.08 | 0 |
| CD20 | 0.66 | 0.50 | 0.70 | 0 | 0 | 0 | 0.50 | 0.28 | 0 | 0.53 | 0 | 0 |
| CD33 | — | 0.48 | 1.12 | 1.40 | 0.50 | 0 | 1.08 | 0.77 | 0 | 0.60 | 0.23 | 0 |
| CD34 | 0.32 | 0.18 | 0.20 | 0.09 | 0 | 0 | 0.15 | 0.09 | 0 | 0.19 | < 0.05 | 0 |
| CD45 | 4.8 | 4.1 | 6.3 | 4.3 | 5.6 | 0.18 | 5.20 | 4.40 | < 0.05 | 4.7 | 0.80 | 0 |
| Gly A | 14.6 | 8.9 | 7.8 | 9.3 | 9.2 | 8.6 | 5.3 | 0.48 | 4.3 | 2.6 | 0 | |
| CFU-GM | 9.8 | 8.4 | 15.6 | 11.7 | 11.7 | 0 | 9.1 | 5.2 | 0 | 7.0 | 2.5 | 0 |
| CFU-Mix | 4.9 | 5.2 | 6.8 | 5.9 | 6.2 | 0 | 5.6 | 3.1 | 0 | 4.4 | 0 | |
Fetal sheep were transplanted with fresh or ex vivo–cultured UCB CD34+ cells from multiple donors. After 2 or 6 months, marrow was obtained and the frequency of human CD45+ cells determined by FACS. As described in “Materials and methods,” CD45+ cells or BMMNC cells were then transferred to secondary and tertiary recipients, respectively. These secondary and tertiary recipients were killed after 2 months and human cell engraftment determined.
Results are derived from a single experiment. Data from groups I to III are the mean results of 2 sheep. Data from groups IV to IX are the mean results from 3 sheep.
CFU-GM indicates colony-forming units-granulocyte macrophage.